Skip to main content
Actuated Medical logo

Actuated Medical

Bellefonte, Pennsylvania, United StatesSee on the mapFounded 2006

  • Series A

Actuated Medical is a clinical-stage medical device company developing technologies to improve patient care. Its NeuralGlider® precision brain access platform uses electronically controlled ultrasonic motion to support accurate delivery of therapies to deep brain targets.

Raised
$11.8M
May 2025
Series A
Investors
5
Founded
2006
Employees
11–50

reccy insights

Recent highlights

Actuated Medical’s clearest recent financing milestone is a $1.5 million Series A announced on May 8, 2025, with Keiretsu Forum named as lead investor. The company’s funding history also includes a grant entry dated Nov 25, 2025 associated with HHS. Its product work spans medical devices for feeding-tube occlusion, tissue penetration, vascular access, MRI-compatible procedures, and precision brain access. NeuralGlider® is described as a brain-access platform using electronically controlled ultrasonic motion to support accurate insertion toward deep brain targets. Preclinical studies have demonstrated precise delivery of AAV gene therapy to deep targets. Publicly available company details do not identify dated partnership announcements, awards, or leadership changes to add to this milestone summary. Nor is there a dated launch announcement included here for NeuralGlider® or the other named technologies. The company is listed as active and has a reported headcount of 23. Taken together, the available dated milestones point to continued device development and a 2025 financing event, but provide limited detail on commercial adoption, clinical progress, or operating changes since then.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes Actuated Medical distinct

  1. 01Develops motion-based medical devices for clinical access and procedure challenges across multiple specialties.
  2. 02NeuralGlider® is a precision brain-access platform using electronically controlled ultrasonic motion to support insertion trajectory.
  3. 03Preclinical studies demonstrated precise delivery of AAV gene therapy to deep brain targets.
  4. 04The platform supports smaller-diameter cannulas for certain applications and is designed to reduce tissue trauma and therapeutic reflux.
  5. 05Product work also addresses feeding-tube occlusions, difficult vascular access, tissue penetration, and MRI-compatible procedures.

Technology & products6

  • NG-Clear

    A system for breaking up occlusions in feeding tubes.

  • PEG-Clear

    A system for breaking up occlusions in feeding tubes.

  • NeuralGlider® Precision Brain Access Platform

    A brain-access platform using electronically controlled ultrasonic motion to support insertion toward deep brain targets.

Research roots1

Labs and research groups this company came from or works with.

  • Pennsylvania State UniversityState College, United States · No page yet
    Founder affiliation
Academic data: Carter Sciences

Funding

$11.8M disclosed
5 investors

Investors9

Also backed by
  • National Heart, Lung, and Blood Institute
  • Charlottesville Angel Network
  • Philadelphia Pediatric Medical Device Consortium

About Actuated Medical

Products
NG-Clear, PEG-Clear, NeuralGlider® Precision Brain Access Platform, Controlled tissue penetration systems, Resonance-assisted vascular entry needles, MRI-compatible systems
Leadership
Maureen MulvihillRoger Bagwell
Focus areas
NeuroTechnology, medical devices, therapeutics, clinical research, neurology, neurosurgery, brain therapy delivery, gene therapy delivery
Headquarters
Bellefonte, Pennsylvania, United States
Founded
2006
Employees
11–50
Status
Active · private